Results 101 to 110 of about 825,494 (348)
Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. [PDF]
The transcription factor Yin Yang 1 (YY1) is frequently overexpressed in cancerous tissues compared to normal tissues and has regulatory roles in cell proliferation, cell viability, epithelial-mesenchymal transition, metastasis and drug/immune resistance.
Bonavida, Benjamin +2 more
core +2 more sources
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad +12 more
wiley +1 more source
Clinicopathological and Immunohistochemical Analysis of Lung Cancer Biopsies at a Tertiary Care Centre in Central Gujarat, India [PDF]
Introduction: Lung biopsy is a reliable and highly accurate tool for diagnosing and subtyping lung lesions. Two-thirds of lung cancer patients present with advanced disease, and small biopsies remain the main diagnostic tool.
Yogita Vrajlal Kareliya +5 more
doaj +1 more source
Exploiting metabolic vulnerabilities of Non small cell lung carcinoma
Lung cancer is the main cause of cancer death worldwide. Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. Given the need for new therapies, the metabolism of NSCLC has been widely studied in the past two decades to identify vulnerabilities that ...
Majem, Blanca +2 more
openaire +3 more sources
Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Lung cancers are broadly divided into small-cell lung cancer (SCLC) and non-SCLC (NSCLC), and the treatments for each differ. NSCLC includes squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others.
K. Kuribayashi, N. Funaguchi, T. Nakano
semanticscholar +1 more source
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Neutrophils dominate the immune cell composition in non-small cell lung cancer
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune checkpoint blockade have been ...
Julia Kargl +10 more
semanticscholar +1 more source

